Founded in 2003, Wilmington PharmaTech (WPT) is a global service provider offering integrated solutions across the entire drug development lifecycle. The company combines the scientific expertise of a contract research organisation (CRO) with the operational efficiency of a contract development and manufacturing organisation (CDMO), delivering end-to-end support for small molecule APIs. With facilities in the United States and China, WPT serves pharmaceutical and biotechnology companies worldwide, providing services from early discovery through to commercial supply.

Headquartered in Newark, Delaware, WPT operates a 54-acre campus featuring state-of-the-art facilities, including high potency API (HPAPI) suites and dedicated research and development spaces. The company also maintains an R&D facility in Suzhou, China, supporting its global operations.

Key Products and Services

• Lead Generation & Medicinal Chemistry: Expertise in scaffold design, prodrug investigation, ADMET optimisation, and SAR development.
• Custom Synthesis & Process Chemistry: Specialising in complex synthesis, solubility enhancement, salt selection, and handling of controlled substances.
• Analytical Services: Integrated analytical support, including method development, validation, ICH stability studies, and impurity identification.
• High Potency API (HPAPI) Manufacturing: Dedicated suites for the production of cytotoxic compounds and antibody-drug conjugates (ADCs).
• Specialty Starting Materials (RSMs): Provision of large-scale, difficult-to-synthesise starting materials and intermediates.
• End-to-End API Development: Seamless support from lead generation to method and process development, scale-up, and cGMP manufacturing.

With a commitment to scientific excellence and operational efficiency, Wilmington PharmaTech continues to be a trusted partner for innovators seeking to overcome complex challenges in drug development and manufacturing. The company's integrated approach and specialised capabilities position it as a valuable asset in the global pharmaceutical and biotechnology sectors.